A 67-year-old patient with a history of depression, anxiety, and bipolar disorder who is taking Depakote (valproic acid) 750 mg each morning, lorazepam 0.5 mg three times daily, duloxetine 30 mg daily, and buspirone 5 mg three times daily is experiencing visual hallucinations of rats; what should be done?

Immediately Evaluate for Drug-Induced Delirium and Consider Stopping or Reducing Lorazepam

This 67-year-old patient's visual hallucinations are most likely drug-induced delirium from chronic benzodiazepine use (lorazepam 0.5 mg TID), potentially compounded by valproate-induced hyperammonemia, and requires urgent medication review with probable benzodiazepine taper and addition of low-dose antipsychotic if hallucinations persist after addressing reversible causes.

Immediate Assessment Steps

1. Rule Out Valproate-Induced Hyperammonemic Encephalopathy

• Check serum ammonia level and valproate level immediately 1, 2
• Valproate can cause elevated ammonia leading to confusion, hallucinations, and altered mental status even at therapeutic drug levels 1
• The FDA label specifically warns that high ammonia levels can "seriously affect your mental activities, slow your alertness, make you feel tired, or cause vomiting (encephalopathy)" 1
• If ammonia is elevated: reduce or discontinue valproate and consider alternative mood stabilizer

2. Identify Benzodiazepine-Induced Delirium

• Lorazepam 0.5 mg TID (1.5 mg/day total) is a significant deliriogenic agent in a 67-year-old 3, 4, 3
• Guidelines explicitly state benzodiazepines "have been identified as deliriogenic" and are "not considered part of the initial strategy in delirium management" 3
• The ESMO guidelines note benzodiazepines cause "increased risk of falls" and may cause "delirium, drowsiness, paradoxical agitation" 3
• Chronic benzodiazepine use in elderly patients substantially increases anticholinergic burden and delirium risk 5

3. Check for Other Reversible Causes

• Electrolytes (especially sodium, calcium)
• Renal and hepatic function
• Complete blood count
• Urinalysis for infection
• Review for recent medication changes or drug interactions

Immediate Management Algorithm

Step 1: Address Benzodiazepine Contribution

Begin slow lorazepam taper (do NOT stop abruptly due to withdrawal seizure risk):

• Reduce by 0.25 mg every 3-5 days
• Monitor for withdrawal symptoms (anxiety, tremor, agitation, seizures)
• Benzodiazepines are first-line only for alcohol/benzodiazepine withdrawal delirium, not for managing hallucinations 3

Step 2: Manage Valproate Issues

If ammonia elevated or valproate level supratherapeutic:

• Reduce valproate dose by 25-50%
• Consider switching to lithium or alternative mood stabilizer if hyperammonemia persists 6
• WHO guidelines support lithium or valproate for bipolar maintenance, allowing flexibility 6

Step 3: Treat Persistent Hallucinations with Antipsychotic

If hallucinations persist after addressing above causes, add low-dose atypical antipsychotic:

Preferred options based on guidelines 3, 7, 3:

• Quetiapine 12.5-25 mg at bedtime (start low in elderly)

  • Less likely to cause extrapyramidal symptoms
  • More sedating (beneficial if sleep disturbed)
  • Available oral only 3

• Olanzapine 2.5 mg at bedtime (alternative)

  • Well-tolerated in elderly
  • Risk of sedation and weight gain 3, 7

• Risperidone 0.25 mg daily (third option)

  • Start very low in elderly
  • Higher risk of extrapyramidal symptoms at doses >2 mg 3, 7

Avoid haloperidol in this patient - while effective for delirium, the 2018 ESMO guidelines found haloperidol and risperidone "not beneficial in cancer patients with mild-to-moderate delirium and have been shown to worsen symptoms" 3. Given this patient's age and polypharmacy, err toward safer atypical agents.

Step 4: Optimize Existing Psychiatric Regimen

• Duloxetine 30 mg daily is a low dose - may be subtherapeutic for depression/anxiety
• Buspirone 5 mg TID (15 mg/day total) is reasonable for anxiety
• However, buspirone FDA label warns about serotonin syndrome risk, especially with duloxetine (SNRI) 8
• Monitor for serotonin syndrome symptoms: agitation, hallucinations, confusion, autonomic instability 8

Critical Pitfalls to Avoid

1. Do NOT add more benzodiazepines - they worsen delirium and increase fall risk in elderly 3, 4, 3

2. Do NOT abruptly stop lorazepam - taper slowly to prevent withdrawal seizures 4

3. Do NOT use typical antipsychotics as first-line - higher risk of extrapyramidal symptoms and may worsen outcomes 3

4. Do NOT overlook valproate toxicity - hyperammonemia can occur even at therapeutic levels and causes psychiatric symptoms 1, 2

5. Do NOT assume hallucinations are psychiatric - always rule out medical causes first (infection, metabolic, drug-induced) 9, 4

Monitoring Plan

• Daily assessment of mental status and hallucination frequency
• Weekly ammonia and valproate levels until stable
• Monitor for benzodiazepine withdrawal symptoms during taper
• Assess for extrapyramidal symptoms if antipsychotic added
• Fall risk assessment (benzodiazepines and antipsychotics both increase falls)
• Monitor for serotonin syndrome given duloxetine + buspirone combination 8

Long-Term Considerations

Once acute delirium resolves:

• Complete benzodiazepine discontinuation if possible - chronic use in elderly associated with cognitive decline, falls, and increased mortality 5
• Optimize bipolar maintenance therapy - valproate 750 mg daily may be adequate, but lithium is equally effective alternative if valproate problematic 6, 10, 11
• Reassess need for all psychotropics - this patient is on 5 psychiatric medications, increasing polypharmacy risks 5
• Consider non-pharmacologic interventions for anxiety (CBT, psychoeducation) 6

The evidence strongly supports that this clinical presentation represents drug-induced delirium requiring medication rationalization rather than addition of more drugs. The combination of chronic benzodiazepine use in an elderly patient plus potential valproate-induced hyperammonemia creates a perfect storm for visual hallucinations and perceptual disturbances.